Viadur Patent Expiration

Viadur is a drug owned by Ortho Mcneil Janssen Pharmaceutical Inc. It is protected by 10 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 17, 2018. Details of Viadur's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6375978 Rate controlling membranes for controlled drug delivery devices
Dec, 2018

(5 years ago)

Expired
US6113938 Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents
Jul, 2018

(6 years ago)

Expired
US6124261 Non-aqueous polar aprotic peptide formulations
Jun, 2017

(7 years ago)

Expired
US5932547 Non-aqueous polar aprotic peptide formulations
Jun, 2017

(7 years ago)

Expired
US6235712 Non-aqueous polar aprotic peptide formulations
Jun, 2017

(7 years ago)

Expired
US5985305 Sustained delivery of an active agent using an implantable system
Jan, 2017

(7 years ago)

Expired
US5728396 Sustained delivery of leuprolide using an implantable system
Jan, 2017

(7 years ago)

Expired
US6395292 Sustained delivery of an active agent using an implantable system
Jan, 2017

(7 years ago)

Expired
US6156331 Sustained delivery of an active agent using an implantable system
Jan, 2017

(7 years ago)

Expired
US6132420 Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
Jan, 2017

(7 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Viadur's patents.

Given below is the list of recent legal activities going on the following patents of Viadur.

Activity Date Patent Number
Patent litigations
Correspondence Address Change 23 Jun, 2016 US6395292
Change in Power of Attorney (May Include Associate POA) 24 Mar, 2015 US6395292
Correspondence Address Change 23 Mar, 2015 US6395292
Correspondence Address Change 26 Feb, 2008 US6395292
Change in Power of Attorney (May Include Associate POA) 31 Jan, 2008 US6395292
Correspondence Address Change 31 Jan, 2008 US6395292
Patent Issue Date Used in PTA Calculation 28 May, 2002 US6395292
Recordation of Patent Grant Mailed 28 May, 2002 US6395292
Issue Notification Mailed 10 May, 2002 US6395292
Receipt into Pubs 02 May, 2002 US6395292

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Viadur is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Viadur's family patents as well as insights into ongoing legal events on those patents.

Viadur's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Viadur's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 17, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Viadur Generic API suppliers:

Leuprolide Acetate is the generic name for the brand Viadur. 8 different companies have already filed for the generic of Viadur, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Viadur's generic

Alternative Brands for Viadur

Viadur which is used for treating prostate cancer., has several other brand drugs using the same active ingredient (Leuprolide Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.


Apart from brand drugs containing the same ingredient, some generics have also been filed for Leuprolide Acetate, Viadur's active ingredient. Check the complete list of approved generic manufacturers for Viadur





About Viadur

Viadur is a drug owned by Ortho Mcneil Janssen Pharmaceutical Inc. It is used for treating prostate cancer. Viadur uses Leuprolide Acetate as an active ingredient. Viadur was launched by Ortho Mcneil Janssen in 2000.

Approval Date:

Viadur was approved by FDA for market use on 03 March, 2000.

Active Ingredient:

Viadur uses Leuprolide Acetate as the active ingredient. Check out other Drugs and Companies using Leuprolide Acetate ingredient

Treatment:

Viadur is used for treating prostate cancer.

Dosage:

Viadur is available in implant form for implantation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 65MG BASE IMPLANT Discontinued IMPLANTATION